# Anteis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anteis

- Industry: Medical Devices & Equipment
- Headquarters: Geneva, Switzerland
- Website: www.anteis.com
- Total disclosed funding: $6M
- Latest round: Series B (May 1, 2009)
- Investors on record: 4

## About

Anteis is a biomedical company specializing in the development and manufacturing of aesthetic products, particularly innovative dermal fillers aimed at enhancing facial aesthetics and rejuvenation.Founded in 2003 in Geneva, Switzerland, Anteis SA focuses on providing advanced biomedical solutions in the aesthetic sector. In November 2013, Merz Pharmaceutical acquired Anteis, integrating its product offerings with a wider portfolio of aesthetic treatments. The company has engaged in three significant funding deals, with the latest being a Series B round in which it raised USD 6.00 mn led by Matignon Investissement et Gestion, alongside investors such as BB Biotech and Signet Healthcare Partners.Anteis SA, under the Merz Aesthetics® brand, specializes in the production of the Belotero® line of dermal fillers. These products are designed for wrinkle filling and skin rejuvenation, integrating seamlessly into the skin for natural results. Additionally, the company offers resorbable implants and skin rehydration gels, improving skin texture and moisture. Its products are available in over 90 countries worldwide, catering to diverse markets including North America, Europe, Asia, and Latin America, targeting aesthetic practitioners, dermatologists, and cosmetic surgeons.Anteis generates revenue primarily through the direct sales of its Belotero® dermal fillers and other aesthetic products to clinics and healthcare providers, maintaining a B2B sales model. The firm's revenue is driven by the increasing global demand for aesthetic treatments, supported by established distribution networks that ensure product availability in various markets. The company's commitment to quality and innovation contributes to its standing in the competitive aesthetic industry.Anteis plans to leverage the recent acquisition by Merz Pharmaceutical to expand its product lines and enhance its market presence. The company aims to introduce new products in the aesthetic sector, with specific timelines yet to be disclosed. Geographic expansion into emerging markets is also part of the strategy, although details regarding targeted regions have not been provided. The recent funding of USD 6.00 mn will support these initiatives, particularly towards product development and market outreach.

## Funding rounds

- Series B, May 1, 2009, $6M — Matignon Investissement et Gestion, BB Biotech, Signet Healthcare Partners
- Series A, Dec 5, 2007 — Houston Ventures, Signet Healthcare Partners

## Investors

- Houston Ventures (https://capitalatlas.ai/funds/houston-ventures) — Series A
- Signet Healthcare Partners (https://capitalatlas.ai/funds/signet-healthcare-partners) — Series A, Series B
- Matignon Investissement et Gestion (https://capitalatlas.ai/funds/matignon-investissement-et-gestion) — Series B
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series B